Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flurbiprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | FABP2 | P12104 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | AKR1C4 | P17516 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tarenflurbil SCHEMBL26131 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Esflurbiprofen SCHEMBL505817 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL1070292 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Tarenflurbil SCHEMBL29350102 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754830 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754978 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL10029029 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8755275 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL3519037 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL9877586 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 79199 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| CN-122031290-A | Percutaneous permeation promoting system and preparation method and application thereof | 北京工商大学 | 2026-05-15 | — | — | CN | claimed |
| US-20260130928-A1 | COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2026-05-14 | — | — | US | claimed |
| CN-122028600-A | Trans perovskite solar cell with fluorine-containing salt interface modification layer and preparation method thereof | 景德镇陶瓷大学 | 2026-05-12 | — | — | CN | claimed |
| EP-3834815-B1 | TOPICAL AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FLURBIPROFEN AND CHLORHEXIDINE | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2026-05-06 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260115145-A1 | Method for Enhancing Drug Solubility and Preparing a Drug Composite Material with Enhanced Solubility | PHARMAEASE TECH LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | claimed |
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NEUROPN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| EP-0039051-A2 | Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1981-11-04 | — | — | EP | claimed |
| EP-0036684-A1 | Derivatives of 4-methyl-5-(2-aminoethyl)-thiomethyl-imidazole having therapeutic activity | Turconi, Franco (IT) | 1981-09-30 | — | — | EP | claimed |
| US-4292319-A | MIXTURE WITH AN ANTIULCER AGENT | BOEHRINGER INGELHEIM GMBH (DE) | 1981-09-29 | — | — | US | claimed |
| EP-0032620-A1 | Process for preparing therapeutic 2-arylpropionic acids and esters, and novel arylmethylmalonate esters | THE UPJOHN COMPANY (US) | 1981-07-29 | — | — | EP | claimed |
| US-4230724-A | 2-/2-FLUORO-4-BIPHENYLYL/PROPIONIC ACID | ALLERGAN PHARMACEUTICALS, INC. (US) | 1980-10-28 | — | — | US | claimed |
| EP-0017169-A1 | Improved anti-inflammatory combinations having reduced ulcerogenicity | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | claimed |
| US-4209638-A | RESOLUTION OF ENANTIOMORPHS | THE BOOTS COMPANY LIMITED (GB) | 1980-06-24 | — | — | US | claimed |
| US-4185100-A | CORTICOSTEROID AND A HYDROTROPIC ACID DERIVATIVE, ENZYME INHIBITORS | JOHNSON & JOHNSON (US) | 1980-01-22 | — | — | US | claimed |
| US-4014993-A | Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds | THE UPJOHN COMPANY (US) | 1977-03-29 | — | — | US | claimed |
| US-3973037-A | Hydratropic acid derivatives in the treatment of non-inflammatory allergic reactions | THE UPJOHN COMPANY (US) | 1976-08-03 | — | — | US | claimed |